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Background: Bronchiolitis is a major health burden in infants globally, particularly
among Indigenous populations. It is unknown if 3weeks of azithromycin improve clinical
outcomes beyond the hospitalization period. In an international, double-blind randomized
controlled trial, we determined if 3weeks of azithromycin improved clinical outcomes in
Indigenous infants hospitalized with bronchiolitis.
Methods: Infants aged 24months were enrolled from three centers and randomized to
receive three once-weekly doses of either azithromycin (30mg/kg) or placebo. Nasopha-
ryngeal swabs were collected at baseline and 48 h later. Primary endpoints were hospital
length of stay (LOS) and duration of oxygen supplementation monitored every 12 h until
judged ready for discharge. Secondary outcomes were: day-21 symptom/signs, respira-
tory rehospitalizations within 6months post-discharge and impact upon nasopharyngeal
bacteria and virus shedding at 48 h.
Results: Two hundred nineteen infants were randomized (n=106 azithromycin, n=113
placebo). No significant between-group differences were found for LOS (median 54 h
for each group, difference=0 h, 95% CI:  6, 8; p=0.8), time receiving oxygen
(azithromycin=40 h, placebo=35 h, group difference=5 h, 95% CI:  8, 11; p=0.7),
day-21 symptom/signs, or rehospitalization within 6months (azithromycin n=31,
placebo n=25 infants, p=0.2). Azithromycin reduced nasopharyngeal bacterial carriage
Abbreviations: CI, confidence interval; DSMB, data safety monitoring board; HRV, human rhinovirus; LOS, length of stay;
NHMRC, National Health and Medical Research Council; NPS, nasopharyngeal swab; PCR, polymerase chain reaction; RCT,
randomized controlled trial; RSV, respiratory syncytial virus.
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(between-group difference 0.4 bacteria/child, 95% CI: 0.2, 0.6; p<0.001), but had no
significant effect upon virus detection rates.
Conclusion: Despite reducing nasopharyngeal bacterial carriage, three large once-
weekly doses of azithromycin did not confer any benefit over placebo during the
bronchiolitis illness or 6months post hospitalization. Azithromycin should not be used
routinely to treat infants hospitalized with bronchiolitis.
Clinical trial registration: The trial was registered with the Australian and New Zealand
Clinical Trials Register: Clinical trials number: ACTRN1261000036099.
Keywords: bronchiolitis, Indigenous, viruses, bacteria, respiratory syncytial virus, macrolides, azithromycin,
randomized controlled trial
Introduction
Bronchiolitis is the most common acute viral lower respiratory
infection in infants worldwide causing more than three million
hospitalizations annually (1). Indigenous children from affluent
countries, such as Australia and New Zealand, are at particular
risk. They are more likely than non-Indigenous children to be
hospitalized (2, 3), to have longer hospital stays (2), to receive
antibiotics for pneumonia (2, 4), and to be rehospitalized in the
next 6months with a respiratory illness (5). Indigenous chil-
dren also have high rates of pneumonia and bronchiectasis (the
latter related to recurrent pneumonia) (6, 7) and their upper
airways are colonized with bacterial pathogens from an early
age (8).
Supportive care, including supplemental oxygen, respiratory
support, and fluid replacement, underpins bronchiolitis man-
agement. Clinical trials have shown bronchodilators, mucolytics,
anti-viral, and anti-inflammatory agents to be ineffective (9).
However, macrolide antibiotics pose as an attractive alternative,
especially for Indigenous infants with their high risk of severe
disease and secondary bacterial complications (5). In addition to
possessing direct antibacterial actions, including activity against
Mycoplasma pneumoniae and Chlamydiales species, macrolides
modulate macrophage, neutrophil, and epithelial cell function
in vitro and in experimental models (10), and possess potential
anti-viral properties. Clarithromycin reduces respiratory syncytial
virus (RSV) receptor numbers on epithelial cell surfaces; while
azithromycin induces interferon-stimulated genes in rhinovirus
(RV)-infected bronchial epithelial cells (11, 12). Finally, a sin-
gle azithromycin dose decreases nasopharyngeal bacterial loads
(5) and transiently reduces the risk of acute lower respiratory
infections in African children following mass trachoma preven-
tion campaigns or when contributing to combination therapy for
malaria (13, 14).
Four placebo, double-blind, randomized controlled trials
(RCTs) have evaluated the efficacy of macrolides in children
hospitalized with bronchiolitis (5, 15–17). The first trial from
Turkey (15), involving 21 infants aged 7months with RSV,
found that clarithromycin daily for 3weeks significantly reduced
hospital length of stay (LOS) and supplemental oxygen and intra-
venous fluid requirements compared to placebo. In contrast, 3
later RCTs (5, 16, 17) involving a total of 352 infants (up to age
2 years) with clinically diagnosed bronchiolitis fromAustralia, the
Netherlands, and Brazil failed to demonstrate any clinical benefit
using azithromycin for 1, 3, or 7 days, respectively. The Turkish
trial was also the only one where treatment extended beyond
the period in hospital where just 1 of the 12 infants in the
clarithromycin group was re-hospitalized compared with 4 of 9
receiving placebo (15).
At the time we started our study, only the RCTs from Turkey
(15) and the Netherlands (16) had been completed. We believed
Indigenous infants were more like high-risk children in Turkey
andmight also benefit froma longer treatment course (theTurkish
study was the only one to have addressed this question) (15).
This is of considerable importance for Indigenous infants where
respiratory symptoms and recurrent hospitalized respiratory ill-
nesses are major risk factors for developing bronchiectasis (5–7).
As administering twice-daily clarithromycin on an ambulatory
basis is impractical in our setting (18), we took advantage of
azithromycin’s long half-life and favorable pharmacokinetics by
opting to determine whether a longer course (three large once-
weekly doses) of azithromycin for Indigenous infants hospitalized
with bronchiolitis improved clinical outcomes (LOS and duration
of oxygen supplementation). Secondary aims were to: (i) deter-
mine the effects of azithromycin on respiratory symptoms and
signs at day-21 and respiratory hospitalizations in the following
6-month period; (ii) assess the short-term impact of azithromycin
upon nasopharyngeal carriage and respiratory virus shedding
and; (iii) describe the viruses, M. pneumoniae and Chlamydiales
species detected in these infants.
Materials and Methods
Study Design and Setting
This was a multi-center, randomized, double-blind, placebo-
controlled trial. Infants were recruited at the Royal Dar-
win (June 2010–September 2013) and Townsville Hospitals
(August 2010–June 2013), Australia and the Auckland Star-
ship Children’s Hospital (November 2012–September 2013),
New Zealand. Human Research Ethics Committees at all par-
ticipating institutions approved the study and caregivers pro-
vided written, informed consent. The study was registered
with the Australian and New Zealand Clinical Trials Register:
ACTRN12608000150347 and monitored by an independent data
safety monitoring board (DSMB).
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Participants
As described in detail previously (19), eligible infants were
aged 24months and hospitalized with a standardized clinical
diagnosis of bronchiolitis (age-adjusted tachypnea with wheeze
or crackles), had parent-ascribed Indigenous ethnicity (Australian
Aboriginal, Torres Strait Islander, Maori, and/or Pacific Islander),
were consented within 24 h of hospitalization and had caregivers
with a mobile phone (see supplement for exclusion criteria and
tachypnea definitions).
Randomization, Allocation and Blinding, and
Medications
An independent statistician used a computer-generated, per-
muted block design to generate randomization sequences. Sealed
opaque envelopes (selecting one of the eight different bottle codes)
concealed the treatment allocation. Infants were allocated in a 1:1
ratio, stratified by age (6 or >6months), oxygen supplemen-
tation on presentation (yes/no) and site (Darwin, Townsville, or
Auckland), to once-weekly doses of oral azithromycin or placebo
for 3weeks. Neither the study team (researchers, hospital staff)
nor parents were aware of assigned treatment groups until data
analysis was completed.
The first dose was given in the hospital (30mg/kg azithromycin
or equal volume of placebo). The remaining two doses were
supervised directly by study nurses (urban-based participants) or
given at home by caregivers (remote-based participants) at weekly
intervals. Study nurses contacted families via mobile phones to
help ensure adherence (20).
Clinical Assessment, Management, and
Outcomes
Demographic, medical history, and clinical data were recorded
on standardized data collection forms. A validated severity score
was employed (see Supplementary Material). Infants with bron-
chiolitis were managed at each site according to a common pro-
tocol, which outlined when supplementary oxygen was indicated
(SpO2 <94%) and when nasogastric feeds or intravenous fluids
were required. The protocol was in place for several months
before commencing the trial. Infants received additional ther-
apies (other than macrolides) at the discretion of the treating
pediatrician.
The primary endpoints of LOS for respiratory illness and dura-
tion of oxygen requirement (where applicable) were monitored
every 12 h. LOS was the time from admission to time “ready
for discharge” from respiratory care as defined by SpO2 >94%
in air for >16 h and feeding adequately. In our setting, “ready
for discharge” from respiratory care can differ from LOS, as
discharge from hospital may be delayed because of non-medical
factors (such as waiting for air transport back to remote commu-
nities). For the other clinical outcomes, the day-21 review was
conducted by study nurses (urban-based participants) and local
health clinic staff (remote-based). Respiratory rehospitalization
within 6months of discharge was recorded through community
and hospital electronic records. Adverse events were monitored
daily in hospital by research staff and following discharge with
weekly phone calls until the day-21 review.
Specimen Collection and Processing
Nasopharyngeal swabs (NPS) taken before initial study medica-
tions were administered and repeated 48 h later, and were pro-
cessed as described previously (21–23) for viruses and atypical
bacteria (C. pneumoniae, Simkania negevensis, M. pneumoniae)
using real-time polymerase chain reaction (PCR) assays (see Sup-
plementary Material for list of viruses). NPS were cultured for
respiratory bacterial pathogens that also underwent antibiotic
susceptibility testing (24).
Sample Size and Analysis
Based upon our previous data where the mean LOS in Indigenous
infants with bronchiolitis was 96 (SD 24) hours (2), we estimated a
total sample of 200 infants (100 in each age sub-group:6months
and >6months) would provide 94% power to detect a difference
in the mean LOS of 12 h between treatment groups at the 5%
significance level (two-tailed) and 95%power to detect a reduction
in respiratory rehospitalization within the next 6months from 30
to 10% (19).
Data were analyzed according to our published protocol. Data
were analyzed according to the group the child was allocated
to. Only available data were analyzed. Between-group differ-
ences were tested using Fisher’s exact test (for proportions)
and Mann–Whitney U test (for continuous variables). A 95%
confidence interval (CI) was obtained for the difference in
medians between treatment groups (25). Subgroup analysis was
performed by age (6 and >6months) as planned (19), and
also for groups based on oxygen requirement when enrolled,
remoteness, antibiotic use, and previous respiratory hospitaliza-
tions for the three clinical outcomes. These post hoc subgroup
analyses were conducted that might inform clinical practice.
p-Values are reported for the subgroup treatment interaction
term in a linear regression model (for log-transformed LOS
and duration of supplemental oxygen) and in a logistic regres-
sion model (for any readmissions within 6months) with main
effects for just treatment group and subgroup. Data were also
analyzed adjusting for significant between-group differences at
baseline.
Results
We recruited 219 infants (106 randomized to azithromycin, 113
to placebo (Figure 1). Overall, 218 received dose-1 in hospital;
102 (azithromycin) and 111 (placebo) received dose-2 and 94
(azithromycin); and 106 (placebo) received dose-3.
Demographical and clinical characteristics were similar
between treatment groups, apart from household smoke
exposure involving more infants in the azithromycin (69%)
than the placebo (50%) group, p= 0.01; see Table 1).
Of the study cohort, 133 (61%) required oxygen during
hospitalization. Non-macrolide antibiotics were prescribed in
93 (43%) infants before hospitalization (see Supplementary
Material) and none received steroids or required intensive
care management. Thirty-eight infants were hospitalized
previously for a respiratory illness (azithromycin: 18; placebo:
20). Retention was high (97%) for the clinical endpoint
at day-21.
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Enrollment
Primary endpoints
• Length of hospitalisation (n=106)
• Duration of supplemental oxygen where applicable 
(n=59/59)
Secondary endpoints
• Day-21 review (n=100)
• Respiratory readmissions (n=106)
• Detection of bacteria and viruses at 48-hrs (n=102)
Primary endpoints
• Length of hospitalisation (n=113)
• Duration of supplemental oxygen where applicable 
(n=74/74)
Secondary endpoints
• Day-21 day review (n=110)
• Respiratory readmissions (n=113)
• Detection of bacteria and viruses at 48-hrs (n=113)
Analysis
Allocated to Placebo (n=113)
• Received allocated placebo (n=113)
• Did not receive allocated Placebo (n=0)
Randomised (n=219)
Admitted for acute lower respiratory tract 
infection (n=698)
Excluded (n=479)
• Did not meet inclusion criteria (n=320)
o Previously enrolled in another RCT (n=20)
o Previously enrolled in this RCT (n=29)
• Declined to participate (n=89)
• Eligible but not approached (n=21)
Allocation
Lost to follow-up 
• Discontinued dose 2 & 3 by medical team (n=2)
• Did not receive azithromycin dose 2 (n=3)
• Did not receive azithromycin dose 3 (n=11)
• Did not attend day-21 review (n=6) 
Allocated to Azithromycin (n=106)
• Received allocated azithromycin (n=105)
• Did not receive allocated Azithromycin (n=1)
o Parents withdrew consent – no doses given
Lost to follow-up 
• Discontinued dose 2 & 3 by medical team (n=1)
• Did not receive placebo dose 2 (n=2)
• Did not receive placebo dose 3 (n=7)
• Did not attend day-21 review (n=3) 
FIGURE 1 | CONSORT flow diagram.
Clinical Outcomes
No significant between-group differences were found for LOS or
duration of supplemental oxygen (Figures 2A,B). The median
LOS of 54 h was identical in both groups (difference= 0 h, 95%
CI:  6, 8; p= 0.8), while the median time receiving oxygen was
40 h in the azithromycin group and 35 h in the placebo group
(difference= 5 h, 95% CI: 8, 11; p= 0.7).
Day-21 Clinical Review and 6-Month Readmission
Two hundred ten (97%) infants completed the day-21 review
(Figure 1). Although persistent symptoms or signs were more
common in placebo group, the between-group differences were
not significant (Table 2).
Overall, 81 (azithromycin n= 47, placebo n= 34)
respiratory rehospitalizations were recorded from 56
participants (azithromycin n= 31, placebo n= 25). No
significant between-group differences were found (odds
ratio for any hospitalization 1.5, 95% CI: 0.8, 3.0, p= 0.2).
Sixty (74%) rehospitalizations were for wheezing-associated
illness.
There was no evidence of a differential effect of azithromycin
on any of the main three clinical outcomes for any of the sub-
groups (see Tables S2–S4 in Supplementary Material). Adjust-
ment for household smoking exposure had negligible effect
on the trial’s main analyses (see Table S5 in Supplementary
Material).
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TABLE 1 |Demographic and clinical characteristics of 219 patients random-
ized to treatment with either azithromycin (n= 106) or placebo (n= 113).
Azithromycin
(n= 106)
Placebo
(n= 113)
Age (months) 5.7 (3–10) 5.6 (3–9)
6months 56 (53%) 61 (54%)
6–24months 50 (48%) 52 (46%)
Male 64 (60%) 72 (64%)
Indigenous Australians 92 (87%) 95 (84%)
New Zealand Maori/Pacific Islander 14 (13%) 18 (16%)
Gestational age (weeks) 38 (36–40) 38 (36–40)
Birth weight (kg) 3.03 (2.3–3.3) 3.00 (2.5–3.4)
Remote region 74 (70%) 71 (63%)
Currently breastfed 82 (78%) 85 (75%)
Mother smoked during pregnancy 54 (51%) 58 (51%)
Exposed to household smoke 72 (69%) 57 (50%)
Previously hospitalized for acute respiratory
infection
18 (17%) 20 (18%)
Symptoms leading up to admission
(reported by parents)
Number of days with symptoms 3 (2–4) 3 (2–4)
Nasal discharge 93 (89%) 96 (85%)
Cough 104 (99%) 110 (97%)
Breathing difficulties 102 (97%) 111 (98%)
Poor feeding 48 (46%) 63 (56%)
Lethargy 52 (50%) 52 (46%)
Baseline clinical severity score (see
Supplementary Material)
5 (4–7) 5 (3–7)
Enrollment observations
Number receiving oxygen 59 (56%) 74 (65%)
Level of supplemental oxygen (L/min) 1 (0.5, 2.0) 1 (0.5, 1.5)
Heart rate (bpm) 152 (137, 164) 147 (138, 156)
Temperature (°C) 36.6 (36.4, 36.9) 36.7 (36.4, 37.0)
Non-macrolide antibiotics prescribed prior to
hospital
47 (45%) 46 (42%)
Non-macrolide antibiotics prescribed during
hospital
64 (61%) 68 (60%)
Supplemental intravenous fluid administered 24 (23%) 23 (20%)
Chest radiograph taken 87 (83%) 88 (78%)
Co-morbidities
Any otitis media 21 (20%) 18 (16%)
Otitis media with perforation 4 (4%) 6 (5%)
Skin infection 32 (30%) 27 (24%)
Anemia 9 (9%) 4 (4%)
Failure to thrive 5 (5%) 6 (5%)
Lobar pneumonia/atelectasis on Chest X-ray 21 (20%) 13 (12%)
Any virus detected 82 (79%) 92 (83%)
Any respiratory bacterial pathogen detected 73 (70%) 83 (73%)
Data are presented as median and inter-quartile range for continuous variables, or actual
numbers (%) for categorical variables.
NB: co-morbidities as documented from hospital admitting medical team. Missing
variables described below.
Azithromycin: gestational age=7 (7%), birth weight=11 (10%), mother smoked during
pregnancy=4 (4%), exposure to household smoke=2 (2%), breathing difficulties=2
(2%), poor feeding=3 (3%), lethargy=12 (11%), enrollment temperature=2 (2%).
Placebo: gestational age=7 (6%), birth weight=9 (8%), number of days with symp-
toms=1 (1%), nasal discharge=4 (4%), breathing difficulties=1 (1%), lethargy=10
(9%), enrollment pulse=1 (1%), temperature=3 (3%), respiratory rate=1 (1%).
FIGURE 2 | (A) Length of hospital stay (LOS) until ready for discharge from
respiratory care. There was no significant difference between children
randomized to azithromycin and placebo. (B) Time children received
supplementary oxygen (where applicable). There was no significant difference
between children randomized to azithromycin and placebo.
Microbiology
Nasopharyngeal swabs were collected from 217 infants at baseline
and 215 at 48 h. At baseline, at least 1 virus was detected in
174 (81%) infants (see Figure S1 in Supplementary Material).
RSV was detected in 91 (42%), followed by HRV (79; 37%) and
adenovirus (14; 7%). The mean number of viruses detected per
infant hardly changed frombaseline to 48 h; azithromycin: 1.0–0.9
viruses (difference 0.1, 95%CI: 0.2, 0.2; p= 0.4); placebo: 1.1–1.0
viruses (difference 0.1, 95%CI: 0.02, 0.3; p= 0.09).
Nasopharyngeal swabs isolations of S. pneumoniae, non-typable
H. influenzae, and M. catarrhalis at 48 h were less common in
the azithromycin group than in the placebo group (Table 3). On
average, there were 0.4 (95%CI: 0.2, 0.6; p< 0.001) fewer bacterial
species per infant in the azithromycin group.
Adverse Events
Three adverse events were reported to our DSMB. In the
azithromycin group, one infant presented to hospital with vom-
iting and diarrhea and another vomited the trial medication. In
the placebo group, one infant presented to hospital with wheezing
and a rash. All recovered and none discontinued the trial.
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TABLE 2 | Persistent respiratory symptoms/signs at day-21 review.
Azithromycin N= 100 (%) Placebo N= 110 (%) Risk difference (95% CI) p- value*
Wet cough 12 (12%) 17 (15%)  4% ( 12%, 5%) 0.4
Crackles/crepitations 7 (7%) 15 (14%)  6% ( 14%, 1%) 0.1
Chest recession 0 (0%) 2 (2%)  2% ( 4%, 0.7%) 0.2
Wheeze 11 (11%) 11 (10%) 1% ( 7%, 9%) 0.9
Any of the above 23 (23%) 35 (32%)  8% ( 20%, 3%) 0.2
*Fisher’s exact test.
TABLE 3 | Nasal swab bacteriology pre- and 48h post-treatment.
Pre-treatment (baseline) Post-treatment (48h)
Azithromycin
n= 104 (%)
Placebo
n=113 (%)
Azithromycin
n= 102 (%)
Placebo
n= 113 (%)
OR Azithromycin vs.
placebo (95% CI)a
p-value**
S. pneumoniae 24 (23) 32 (28) 6 (6) 24 (21) 0.2 (0.06, 0.5) 0.001
Penicillin intermediate resistant 11 (11) 11 (10) 3 (3) 8 (7) 0.2 (0.05, 1.2) 0.2
Penicillin resistant 1 (1) 0 (0) 1 (1) 1 (1) – 1.0
Azithromycin resistant 6 (6) 6 (5) 3 (3) 6 (5) 0.3 (0.03, 2.02) 0.5
Non-typable H. influenzae 38 (37) 43 (38) 10 (10) 34 (30) 0.2 (0.07, 0.4) <0.001
Azithromycin resistant 0 (0) 1 (1) 0 (0) 0 (0) – –
Ampicillin resistant 8 (8) 8 (7) 1 (1) 9 (8) 0.02 (0.001, 0.4) 0.02
Beta-lactamase positive 8 (8) 8 (7) 1 (1) 9 (8) 0.02 (0.001, 0.4) 0.02
M. catarrhalis 33 (32) 50 (44) 12 (12) 41 (36) 0.2 (0.08, 0.5) <0.001
Beta-lactamase positive 30 (29) 50 (44) 12 (12) 41 (36) 0.2 (0.1, 0.6) 0.001
S. aureus 11 (11) 15 (13) 10 (10) 17 (15) 0.6 (0.2, 1.6) 0.3
Erythromycin non-susceptible 2 (2) 6 (5) 4 (4) 7 (6) 0.8 (0.2, 3.0) 0.5
MRSA 2 (2) 4 (4) 1 (1) 6 (5) 0.1 (0.007, 2.0) 0.1
OR, odds ratio.
Four infants not counted in table results (i.e., refused, missed).
Minimum inhibitory concentrations determined for S. pneumoniae and non-typable H. influenzae (NTHi), and breakpoints defined using European Committee on Antimicrobial
Susceptibility Testing (EUCAST) (http://www.eucast.org): S. pneumoniae, intermediate penicillin resistant, MIC >0.06–2mg/L, penicillin resistant, MIC >2mg/L, and azithromycin
resistant MIC >0.5mg/L; and for H. influenzae, azithromycin resistant, MIC >4mg/L and ampicillin resistant, MIC >1mg/L.
aLogistic regression – difference between treatment groups at post-treatment (48 h).
**p-value from Fisher’s exact test.
Discussion
This is the first international, multicentre, double-blind RCT of
an extended course of macrolides in bronchiolitis. In this study
involving 219 Indigenous infants, we found that three once-
weekly doses of azithromycin (compared to placebo), conferred
no benefit in terms of LOS, duration of oxygen supplementation,
day-21 symptom/signs, or respiratory rehospitalizations within
6months post discharge. Azithromycin significantly reduced the
mean number of nasopharyngeal bacteria per infant, but not the
mean number of viruses per infant.
Our study is larger than the four preceding published studies
on macrolides in bronchiolitis (5, 15–17) and involved a group
of infants from populations at high risk for chronic suppurative
lung disease (6). Our findings on the lack of beneficial effect
of azithromycin for hospital-based outcomes (LOS and duration
of oxygen supplementation) are concordant with three of these
studies (5, 16, 17). To date, the Turkish study is unique (15)
where 3weeks of clarithromycin reported reduced LOS, oxygen
supplementation, and respiratory rehospitalization within the fol-
lowing 6months. Possible reasons for the difference between the
Turkish (15) and other studies (5, 16, 17) include: using clar-
ithromycin with its greater lung penetration and potential anti-
RSV activity (11), differences in sample size, attrition population
characteristics, the role of chance, and increased risk of bias
associated with small studies.
We used a longer course of azithromycin than the other
studies (5, 15–17) and did not find any clinically significant
between-group outcomes. Azithromycin had no significant effect
on the presence of persistent symptoms/signs on day-21 review
and the proportion with persistent respiratory symptoms or
signs (14–24%) are similar to another report of 25% infants
remaining symptomatic after 21 days (26). Furthermore, the
importance of the symptoms beyond hospitalization of per-
sistent cough and wheeze was highlighted in a guideline on
bronchiolitis (27).
The proportion of respiratory rehospitalizations within
6months of discharge (25%) was also similar to other trials
(5, 15). Rehospitalization for respiratory illness is an important
outcome because it is an independent risk factor for bronchiectasis
in Indigenous children (6). We targeted this high-risk group, as
respiratory diseases are prevalent and more severe and persistent
in this population (5, 28).
The mean number of nasopharyngeal respiratory bacteria was
reduced more in the azithromycin than the placebo arm, as seen
in our previous short-term RCT (5). Although the number of
macrolide-resistant bacteria at 48 h also declined, this was not
to the same extent as found in susceptible strains. Meanwhile,
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detection rates for respiratory viruses between treatment groups
changed little over the 48 h following enrollment, though PCR
detects nucleic acids, it is not possible to determine whether
differences in viable viruses existed with azithromycin treat-
ment.
Our study has several other limitations, which may have
resulted in the negative results of our RCT. First, including
an older age group increased the risk of including those with
asthma. However, our cohort’s median age of 6months (IQR 3,
9) reduced this possibility. Further, in both the UK and USA
bronchiolitis guidelines, the upper age limit is 23–24months.
Second, in the Australian centers, we included those hospital-
ized previously for an acute respiratory infection, which may
have contributed to the number of respiratory rehospitalizations
(27, 29). Third, the concurrent use of antibiotics in two-thirds
of infants with bronchiolitis may limit the ability of additional
macrolide treatment to improve outcomes. We were unable to
influence the clinical practice of physicians on this matter. How-
ever, subgroup analyses on previous respiratory hospitalization,
or antibiotic use did not show any significant differences on
any of our outcomes (see Supplementary Material). Fourth, our
strategy of using three large once-weekly azithromycin doses may
have produced sub-optimal results. This, however, is unlikely
as prior RCTs of daily azithromycin found no benefit (16, 17).
Moreover, in children, single large doses of azithromycin can
successfully treat otitis media (18), while for several weeks after
its mass distribution within rural African villages for controlling
trachoma, azithromycin reduced the risk of acute lower respira-
tory infections by more than one-third (13). Although our RCT
(18) used the same regime for long-term therapy of children
with bronchiectasis and showed that azithromycin significantly
reduced the exacerbation rate by 50% (compared to placebo),
the different disease and younger age group in this RCT meant
an alternative dose and/or regime for optimal efficacy may have
been required. Finally, even though parents reported verbally that
doses-2 and 3 were given, we were unable to directly observe
these for remote-based infants (n= 145). However, the day-21
follow-up rate of >97% at the local health clinic implies that
parents are likely to have adhered to the study protocol. This
is supported by feedback from research nurses who interviewed
parents throughout the trial.
Our study was aimed at infants at high risk of future bronchiec-
tasis and employed a 3-week equivalent course in a multicentre
setting. This design was to maximize the chances of demonstrat-
ing a clinical benefit for azithromycin in our target population,
by reducing subsequent hospitalization and shortening hospital
stay (both are independent risk factors for later development
of bronchiectasis). Despite this, no advantage from receiving
azithromycin was identified. Moreover, there are now growing
concerns over the increasing global consumption of antibiotics
and rising rates of antibiotic resistance, especially when few new
anti-microbial agents are in the developmental pipeline (30, 31).
Much of this antibiotic resistance is being driven by antibiotics
prescribed for viral respiratory infections, most notably long-
acting, broad-spectrum agents, including azithromycin (32, 33).
An emerging fear for this young age group is that antibiotics
may also adversely affect the developing intestinal “microbiome”
with potential deleterious long-term effects upon gastrointestinal,
immunological, and metabolic programing (34). Thus, given our
study’s negative findings and the concerns over the association
between azithromycin and increased carriage of macrolide-
resistant pathogens (35), the increasing need for anti-microbial
stewardship, potential immediate and long-term adverse events,
and associated costs, it is clear that these factors outweigh any
postulated, but still unproven benefits ofmacrolides in this patient
population.
Conclusion
In this RCT of Indigenous infants hospitalized with bronchiolitis,
we found that three once-weekly doses of azithromycin signifi-
cantly reduced nasopharyngeal bacterial carriage, but did not have
any significant impact on viruses or short (reduced LOS or dura-
tion of oxygen supplementation) or long-term (decreased odds
of persistent symptoms at day-21 or respiratory rehospitalization
within 6months of discharge) clinical benefits compared with
placebo. In light of these results, similar findings in other studies,
and fears over rising antibiotic resistance, azithromycin should not
be used to treat infants hospitalized with viral bronchiolitis.
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